In squamous cell carcinoma, it has been shown that EGFR inhibitors (gefitinb and erlotinb) decrease VEGF expression via Hypoxia-inducible factor 1-alpha (HIF1α)54, a direct upstream regulator for VEGF transcription55. The gene discussed is EGFR; the disease is squamous cell carcinoma.